A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs

NCT04538313 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

NETWORK

Sponsor class

Conditions

Hepatic Carcinoma

Interventions

DRUG: Tumor infiltrating lymphocyte

Sponsor

CAR-T (Shanghai) Cell Biotechnology Co., Ltd.

Collaborators

[object Object]